Ολλανδία - Ολλανδικά - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

glaxosmithkline b.v. van asch van wijckstraat 55h 3811 lp amersfoort - paroxetinehydrochloride 0,5-water samenstelling overeenkomend met ; ; paroxetine 30 mg/stuk - filmomhulde tablet - calciumwaterstoffosfaat 2-water (e 341) ; hypromellose (e 464) ; indigokarmijn (e 132) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; polyethyleenglycol (e 1521) ; polysorbaat 80 (e 433) ; titaandioxide (e 171), calciumwaterstoffosfaat 2-water (e 341) ; hypromellose (e 464) ; indigokarmijn (e 132) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; polyethyleenglycol (e 1521) ; polysorbaat 80 (e 433) ; titaandioxide (e 171) - paroxetine

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

accord healthcare s.l.u (0000009808) moll de barcelona, edifici est s/n, planta 6, barcelona, 08039 - paracetamol - tablets - 500mg - paracetamol (0000103902) 500mg - paracetamol

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

baxter holding b.v., the netherlands kobaltweg 49, 3542ce utrecht - paracetamol - sol.inf (ΔΙΑΛΥΜΑ ΓΙΑ ΕΓΧΥΣΗ) - 10mg/ml - paracetamol 10mg - paracetamol

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

baxter holding b.v., the netherlands kobaltweg 49, 3542ce utrecht - paracetamol - sol.inf (ΔΙΑΛΥΜΑ ΓΙΑ ΕΓΧΥΣΗ) - 10mg/ml - paracetamol 10mg - paracetamol

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

primus pharmaceuticals, inc. - genistein (unii: dh2m523p0h) (genistein - unii:dh2m523p0h), zinc glycinate citrate (unii: h3472pj7ya) (zinc cation - unii:13s1s8sf37), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - genistein 27 mg - each fosteum capsule contains 27 mg of genistein aglycone (genistein), derived from a natural source, for a total daily intake of 54 mg. in clinical trials, this level of intake has been shown to increase bone mineral density (bmd). genistein is chemically described as 4',5,7-trihydroxyisoflavone or 5,7-dihydroxy-3-(4-hydroxyphenyl)-4h-1-benzopyran-4-one. it is the aglycone form of the glucoside isoflavone molecule genistin. the empirical formula of genistein is c15 h10 o5 ; its molecular weight is 270.2. the structural formula is: each fosteum capsule contains 20 mg citrated zinc bisglycinate, a glycine amino acid chelate of zinc formed in the presence of citric acid that provides approximately 4 mg of elemental zinc per capsule. zinc is an essential mineral co-factor required by enzymes involved in bone metabolism and has important physiological functions in other tissues throughout the body. elemental zinc has also been shown to have synergistic effects with genistein on bone formation. this zinc bisglycin

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hameln pharmaceuticals - pentetate zinc trisodium (unii: nxu65ic8pg) (pentetic acid - unii:7a314hqm0i) - injection, solution, concentrate - 200 mg in 1 ml - zn-dtpa is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. none known.

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - zinc oxide - cutaneous cream - 320mg/1gram

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

par pharmaceutical, inc. - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 10 mg - oxycodone hcl extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - •because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve oxycodone hcl extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - •oxycodone hcl extended-release tablets are not indicated as an as-needed (prn) analgesic oxycodone hcl extended-release tablets are contraindicated in patients with: - •significant respiratory depression - •acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment - •know

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

par pharmaceutical inc. - modafinil (unii: r3uk8x3u3d) (modafinil - unii:r3uk8x3u3d) - modafinil 100 mg - modafinil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (osa), or shift work disorder (swd). limitations of use in osa, modafinil is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. if continuous positive airway pressure (cpap) is the treatment of choice for a patient, a maximal effort to treat with cpap for an adequate period of time should be made prior to initiating and during treatment with modafinil for excessive sleepiness. modafinil is contraindicated in patients with known hypersensitivity to modafinil or armodafinil or its inactive ingredients [see warnings and precautions (5.1, 5.2, 5.3)] . pregnancy category c there are no adequate and well-controlled studies of modafinil in pregnant women. intrauterine growth restriction and spontaneous abortion have been reported in association with modafinil (a mixture of r- and s-modafinil) and armodafinil (the r-enantiomer of modafi

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

par pharmaceutical, inc. - diclofenac potassium (unii: l4d5ua6cb4) (diclofenac - unii:144o8ql0l1) - diclofenac potassium 50 mg - diclofenac potassium for oral solution is indicated for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older). limitations of use - diclofenac potassium for oral solution is not indicated for the prophylactic therapy of migraine. - the safety and effectiveness of diclofenac potassium for oral solution have not been established for cluster headache, which is present in an older, predominantly male population. diclofenac potassium for oral solution is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product [see warnings and precautions (5.7, 5.9)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)] - in the setting of coronary artery bypass graft (cabg) surgery [se